Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Prof Wynand Goosen
Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards.

Being nominated for a ‘Science Oscar’ is exciting and validates nominees’ efforts, particularly in a field as challenging and essential as infectious diseases, for which they are recognised at the highest level. 

This is according to Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State (UFS). He was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards for his landmark discovery of Mycobacterium bovis infection in humans in South Africa – the first confirmed cases in the country. 

Prof Goosen, who previously won the NSTF-South32 Emerging Researcher Award, says the nomination is a powerful affirmation of the impact that focused, interdisciplinary research can have. It reflects not only his personal commitment but also the dedication of a talented and hard-working team. “I am honoured and humbled to be nominated. It is also a testament to the support and vision of UFS, particularly as we position ourselves as leaders in One Health research in South Africa,” he says. 

 

Focus of research 

He was nominated by Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation, and Prof Paul Oberholster, Dean for the Faculty of Natural and Agricultural Sciences (NAS) at the UFS, and Prof Nico Gey van Pittius and Prof Elmi Muller from Stellenbosch University (US). The NSTF Awards, known as the ‘Science Oscars’of SA, honour, reward, celebrate, profile and promote outstanding contributions to science, engineering and technology (SET) and innovation in South Africa.

“The nomination,” Prof Goosen continues, “recognises our work in the field of zoonotic tuberculosis (TB) and other emerging infectious diseases at the human-animal-environment interface. Our research focuses on the molecular detection and characterisation of pathogenic mycobacteria in wildlife, livestock, and human populations, with the aim of informing better surveillance, diagnostics, and control strategies — particularly in high-risk ecosystems. This includes novel applications in wildlife TB surveillance and understanding the transmission dynamics between animals and people.”

 

Establishing a Kovsie One Health Research Unit

This research is critically important as South Africa continues to face a high burden of tuberculosis, including zoonotic TB, which often goes under-detected in rural and wildlife-rich areas. Understanding how these pathogens circulate between humans, animals, and the environment, explains Prof Goosen, is essential for effective disease control and to mitigate future pandemics. This work directly supports national health priorities, informs policy, and contributes to global strategies for One Health.

Prof Goosen and the team are in the process of laying the groundwork for the establishment of a Kovsie One Health Research Unit, which will serve as a collaborative platform for research spanning human, animal, and environmental health. One of their key projects involves expanding TB and AMR surveillance in wildlife-livestock-human interfaces, using cutting-edge diagnostics and genomic tools. They are also initiating partnerships with industry and international institutions to address emerging zoonoses and environmental pathogens in a transdisciplinary manner.

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept